Novel pyrrolopyridinone derivatives as anticancer inhibitors towards Cdc7: QSAR studies based on dockings by solvation score approach

Kim, 2008, Cdc7 kinase mediates Claspin phosphorylation in DNA replication checkpoint, Oncogene, 27, 3475, 10.1038/sj.onc.1210994 Vanotti, 2008, Cdc7 kinase inhibitors: pyrrolopyridinones as potential antitumor agents. 1. Synthesis and structure-activity relationships, J. Med. Chem., 51, 487, 10.1021/jm700956r Jiang, 1999, Mammalian Cdc7-Dbf4 protein kinase complex is essential for initiation of DNA replication, Embo J., 18, 5703, 10.1093/emboj/18.20.5703 Bonte, 2008, Cdc7-Dbf4 kinase overexpression in multiple cancers and tumor cell lines is correlated with p53 inactivation, Neoplasia, 10, 920, 10.1593/neo.08216 Johnston, 1999, First the CDKs, now the DDKs, Trends Cell. Biol., 9, 249, 10.1016/S0962-8924(99)01586-X Oshiro, 1999, Cell cycle control of Cdc7p kinase activity through regulation of Dbf4p stability, Mol. Cell Biol., 19, 4888, 10.1128/MCB.19.7.4888 Ferreira, 2000, Dbf4p, an essential S phase-promoting factor, is targeted for degradation by the anaphase-promoting complex, Mol. Cell Biol., 20, 242, 10.1128/MCB.20.1.242-248.2000 Ermoli, 2009, Cell division cycle 7 kinase inhibitors: 1H-pyrrolo[2,3-b]pyridines, synthesis and structure-activity relationships, J. Med. Chem., 52, 4380, 10.1021/jm900248g Montagnoli, 2006, Identification of Mcm2 phosphorylation sites by S-phase-regulating kinases, J. Biol. Chem., 281, 10281, 10.1074/jbc.M512921200 Charych, 2008, Inhibition of Cdc7/Dbf4 kinase activity affects specific phosphorylation sites on MCM2 in cancer cells, J. Cell Biochem., 104, 1075, 10.1002/jcb.21698 Montagnoli, 2004, Cdc7 inhibition reveals a p53-dependent replication checkpoint that is defective in cancer cells, Cancer Res., 64, 7110, 10.1158/0008-5472.CAN-04-1547 Swords, 2010, Cdc7 kinase – a new target for drug development, Eur. J. Cancer, 46, 33, 10.1016/j.ejca.2009.09.020 Montagnoli, 2008, A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity, Nat. Chem. Biol., 4, 357, 10.1038/nchembio.90 Afroz Alam, 2009, Molecular modelling evaluation of the cytotoxic activity of podophyllotoxin analogues, J. Comput. Aided Mol. Des., 23, 209, 10.1007/s10822-008-9252-1 Menichincheri, 2009, First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2 Lead discovery, J. Med. Chem., 52, 293, 10.1021/jm800977q Zeng, 2010, Combined 3D-QSAR modeling and molecular docking study on 1,4-dihydroindeno[1,2-c]pyrazoles as VEGFR-2 kinase inhibitors, J. Mol. Graph. Model., 29, 54, 10.1016/j.jmgm.2010.04.004 Zeng, 2011, Molecular modeling studies on benzimidazole carboxamide derivatives as PARP-1 inhibitors using 3D-QSAR and docking, Chem. Biol. Drug. Des., 78, 333, 10.1111/j.1747-0285.2011.01139.x Pratim Roy, 2009, On two novel parameters for validation of predictive QSAR models, Molecules, 14, 1660, 10.3390/molecules14051660